Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Treat severe cases of infection at COV with XAV-19

Project description

Polyclonal antibodies for the treatment of COVID-19 infection

Polyclonal antibodies are very efficient and superior to monoclonal antibodies as a treatment option for bacterial or viral infectious diseases. French company XENOTHERA has developed a platform for the production of glyco-humanised polyclonal antibodies with high efficiency and optimised safety. Currently, XENOTHERA is working on the development of a new treatment against COVID-19 based on this technology. The product, XAV-19, is expected to treat patients suffering from moderate to severe pneumonia. The purpose of the EU-funded BRIGHT project is to prepare the product and complete all necessary actions for a phase 2 double-blind clinical trial to demonstrate its efficacy.

Objective

Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimized safety.
It has been known for decades that polyclonal antibodies are very efficient weapons in infectious diseases, either bacterial or viral, and they are established as superior to monoclonal in various viral infections.
Since the beginning of the pandemic XENOTHERA has initiated a project to develop a new treatment against COVID-19 based on its technology. The product is named XAV-19 and is expected to treat patients suffering from moderate to severe pneumonia.
The purpose of BRIGHT is to prepare the product, run all necessary investigation so that we can safely run a clinical trial demonstrating the efficacy of the product. This will be a phase 2 double-blind clinical trial of XAV19 versus placebo. The endpoint will be the quick recovery of patients admitted at the hospital.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

XENOTHERA
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 162 650,00
Address
1 RUE VAUBAN
44000 Nantes
France

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Pays de la Loire Pays de la Loire Loire-Atlantique
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 3 127 625,00
My booklet 0 0